Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
4
67%
Ph early_phase_1
1
17%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 24 (66.7%)

Trials by Status

completed467%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

NCT03880474
completedphase_2

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

NCT03883113
terminatedphase_2

Improved Novel VaccIne CombinaTion InflUenza Study

NCT03300362
completedearly_phase_1

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

NCT03277456
completedphase_1

A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults

NCT00942071
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03880474Phase 2

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Terminated
NCT03883113Phase 2

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Completed
NCT03300362Phase 2

Improved Novel VaccIne CombinaTion InflUenza Study

Terminated
NCT03277456Early Phase 1

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

Completed
NCT00942071Phase 1

A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults

Completed
NCT00993083Phase 2

A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6